Halelujah! We broke 80 cents!, page-40

Why would you just assume ddRNAi is a complete failure by just one trial failing? TT-034 failing could be because of a multitude of reasons many of them not being because ddRNAi is a failure. You know they do have multiple other drugs in discovery and preclinical right? Lets put it this way if TT-034 is a failure and they don't raise the money they will surely be done for. If it is a failure and they do raise money it would be a staggering price decline however they would have a chance of recovering down the road if it was because of a reason other than ddRNAi being a failure. In my opinion you seem very short sighted and are putting way too much weight on TT-034. The company is much more than this one drug. If you actually think 100 million dollars can't be put to use getting another drug into the clinic this conversation is really pointless.